Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors
May 10 2022 - 8:30AM
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE:
CWY0) (“
Clearmind” or the
"
Company"), a biotech company focused on discovery
and development of novel psychedelic-derived therapeutics to solve
major undertreated health problems, today announced the filing of a
provisional patent application, related to a psychedelic
combination therapy treating binge behaviors that results from its
recently launched collaboration with SciSparc Ltd. (NASDAQ: SPRC).
SciSparc is a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system. The patent
application refers to the combination of Clearmind's MEAI, a novel
proprietary psychedelic treatment for addictions and binge
behaviors with SciSparc's CannAmide™.
The patent application followed a successful
pre-clinical study that showed a significant dose-dependent effect
for MEAI treatment in reducing alcohol consumption of treated
animals, with additional significant effect for the CannAmide™
treatment at the lower, sub-effective MEAI dose.
"Clearmind continues to expand its IP portfolio
and pave its way as the holder of the most significant patent
portfolio in the industry,” said Dr. Adi Zuloff- Shani, Clearmind's
Chief Executive Officer. “Clearmind’s patent portfolio, built
around technologies we developed, is unique in the psychedelic
field. This patent application results from the successful
pre-clinical results we announced in March, making a wider
collaboration with SciSparc a natural progression."
Initial results of the pre-clinical, on mice,
study showed that alcohol consumption was significantly reduced
following treatment with MEAI at a dose of 40 mg/kg and at higher
doses (p<0.01) compared to consumption before treatment. Alcohol
consumption was significantly reduced following dual treatment with
25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg,
again compared to consumption before treatment.
The mice were provided with 20% alcohol solution
for 24 hours three times a week for seven weeks, and were treated
every day with MEAI or the combination of MEAI and CannAmide™
during the last two weeks of alcohol treatment. The alcohol
consumption was measured by weighing the alcohol bottles before and
after; and water consumption was measured similarly in
parallel.
About Clearmind Medicine Inc.
Clearmind is a new biotech company focused on
the discovery and development of novel psychedelic-derived
therapeutics to solve widespread and underserved health problems,
including alcohol use disorder.
The Israeli- Canadian company holds several
patents, among other, for the non-hallucinogenic compound MEAI. The
company intends to seek additional patents for its compounds
whenever warranted and will remain opportunistic regarding the
acquisition of additional intellectual property to build its
portfolio.
Shares of Clearmind are listed for trading on
the Canadian Securities Exchange under the symbol "CMND", the
Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC
pink under the symbol "CMNDF".
About SciSparc
(NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of
Tourette syndrome, for the treatment of obstructive sleep apnea and
Alzheimer's disease and agitation; SCI-160 for the treatment of
pain; and SCI-210 for the treatment of autism spectrum disorder and
status epilepticus.
For further information, please contact:
Investor
Relationsinvest@clearmindmedicine.comTelephone: (604)
260-1566General
InquiriesInfo@Clearmindmedicine.comwww.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking
statements and information based on current expectations. These
statements should not be read as guarantees of future performance
or results. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements. Such statements include submission of
the relevant documentation within the required timeframe to the
satisfaction of the relevant regulators and raising sufficient
financing to complete the Company's business strategy. There is no
certainty that any of these events will occur. Although such
statements are based on management's reasonable assumptions, there
can be no assurance that such assumptions will prove to be correct.
We assume no responsibility to update or revise them to reflect new
events or circumstances.
Investing into early-stage companies inherently
carries a high degree of risk, and investment into securities of
the Company shall be considered highly speculative.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of the securities in any province in which such offer,
solicitation or sale would be unlawful. The securities issued, or
to be issued, under the Private Placement have not been, and will
not be, registered under the United States Securities Act of 1933,
as amended, and may not be offered or sold in the United States
absent registration or an applicable exemption from registration
requirements.
Neither the Canadian Securities Exchange (the
“CSE”) nor its Regulation Services Provider (as that term is
defined in the policies of the CSE) accepts responsibility for the
adequacy or accuracy of this release.
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Sep 2023 to Sep 2024